Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
BIRC3
REST API REST API
Homo sapiens
BIRC3 is differentially expressed in 320 experiments: 115 organism parts: bone marrow, lymph node, ... (113 more);, 180 disease states: normal, Burkitt's lymphoma, ... (178 more);, 100 cell types 415 cell lines 49 compound treatments and 73 other conditions.
Synonyms cIAP2, API2, c-IAP2, MALT2, MIHC, RNF49, hiap-1
Orthologs BIRC3 (Bos taurus)   Birc3 (Rattus norvegicus)   ENSCING00000005622 (Ciona intestinalis)   Iap2 (Drosophila melanogaster)   Q9IA70_CHICK (Gallus gallus)   Birc3 (Mus musculus)   birc2 (Danio rerio)   th (Drosophila melanogaster)   birc2 (Xenopus laevis)   BIRC3_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, cytoplasm, intracellular, protein ubiquitination, metal ion binding, anti-apoptosis, cell surface receptor linked signaling pathway, nucleus, ubiquitin-protein ligase activity, zinc ion binding, regulation of apoptosis
InterPro Term Znf_RING, CARD, BIR
UniProt Accession Q13489
Search EB-eye ENSG00000023445
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-GEOD-7224, E-GEOD-1577, E-GEOD-7540, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (43 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-5823, E-GEOD-20081, E-GEOD-19639
SW480
3
E-MEXP-1014, E-GEOD-18005, E-MTAB-37
A549
2
E-GEOD-3202, E-GEOD-6013
DU145
2
E-GEOD-17482, E-GEOD-20089
LNCaP
2
E-GEOD-14990, E-GEOD-14464
T84
2
E-MTAB-37, E-GEOD-1474
409 more value(s).


Cell type

studied in E-GEOD-22373, E-MEXP-750, E-GEOD-13909, E-GEOD-20677, E-GEOD-13987, ... (45 experiments)

Factor Value U/D Experiments
stromal cell
2
E-MEXP-2034, E-GEOD-1460
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
CD19+ B cells (neg. sel.)
2
E-AFMX-5, E-TABM-145
CD4+ T cell
1
2
E-GEOD-6740, E-GEOD-16190, E-AFMX-5
mononuclear
1
E-GEOD-13987
immortalised T lymphocytes
1
E-GEOD-13909
94 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-1577, E-GEOD-16363, E-MTAB-62, E-MTAB-680, ... (56 experiments)

Factor Value U/D Experiments
acute promyelocytic leukemia
3
E-GEOD-96, E-GEOD-995, E-MTAB-62
control
3
E-GEOD-21912, E-GEOD-8121, E-GEOD-16363
gastric carcinoma
2
E-GEOD-15460, E-GEOD-2685
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
neuroblastoma
2
E-MTAB-37, E-MTAB-62
174 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-2639, E-GEOD-1417, E-GEOD-5741, E-GEOD-3720, ... (32 experiments)

Factor Value U/D Experiments
none
5
8
E-TABM-868, E-MEXP-1958, E-MEXP-1230, E-GEOD-5099, E-MEXP-1269, ... (13 experiments)
ethanol
2
E-MEXP-2241, E-GEOD-3113
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
tumor necrosis factor
2
E-GEOD-2639, E-GEOD-2638
lipopolysaccharide and R848
1
E-GEOD-2706
galectin-1
1
E-GEOD-4984
43 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
81
2
1
E-GEOD-3494
32
1
1
E-GEOD-3494
28
1
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (11 experiments)

Clinical info
studied in E-GEOD-19743, E-GEOD-22513, E-MEXP-1251, E-GEOD-21374, E-GEOD-1563, ... (14 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-3140, E-GEOD-2666, E-MEXP-2283, E-MEXP-958, E-MEXP-1082, ... (6 experiments)

Disease staging
studied in E-GEOD-89, E-GEOD-1323, E-GEOD-19743, E-GEOD-7788, E-GEOD-22148, ... (10 experiments)

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7578, E-GEOD-20847, E-MEXP-2340

Genotype
studied in E-TABM-1029, E-GEOD-17476, E-GEOD-20115, E-TABM-868, E-GEOD-18005, ... (17 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-13073, E-GEOD-21612, E-TABM-127, E-GEOD-20504, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-740, E-GEOD-1926, E-MEXP-2069, ... (31 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-MEXP-561, E-GEOD-980, E-GEOD-17400, ... (8 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-22229, E-GEOD-4525, E-GEOD-19703, E-GEOD-21750, ... (9 experiments)

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343, ... (6 experiments)

pt
studied in E-GEOD-21653

Qpcr egfr dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-MEXP-548, E-GEOD-3697 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70, E-GEOD-18995

Sex
studied in E-GEOD-19743, E-GEOD-16363

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-23984, E-GEOD-11428 ... (5 experiments)

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-33562, E-GEOD-22152, E-GEOD-19246, E-GEOD-13818

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-22541, E-GEOD-1561, E-GEOD-4922

Processing time: 0.286 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM